Series AHealthUnited StatesJun 08, 2026

Kanvas Biosciences raises $48.0M Series A (United States, Jun 2026)

$48.0M
$48 million Series A
Browse investors in United States →
Generated social card
Kanvas Biosciences social card
Headline

Kanvas Biosciences raises $48 million to advance microbiome cancer therapies - Cornell Chronicle

About

Kanvas Biosciences is focused on developing microbiome-based cancer therapies, leveraging a breakthrough imaging platform to map the gut microbiome. The company aims to improve cancer immunotherapy outcomes and address malnutrition-related gut diseases, with its foundational technology emerging from research at Cornell University.

Article summary

Kanvas Biosciences raises $48 million to advance microbiome cancer therapies  Cornell Chronicle

Founder
Hao Shi
Co-founder
Investors · 2
DCVCLead
FUND
Lions Capital
FUND
Related rounds
Jun 28, 2026Delphi Digital$40.0MSeries BUnited States
Jun 27, 2026Hera$27.0MSeries AUnited States
Jun 27, 2026Securitize$400.0M—United States
Jun 27, 2026Generate Biomedicines$700.0MSeries CUnited States
Kanvas Biosciences raises $48.0M Series A (United States, June 2026) | Datapile